acyl-CoA synthetase short chain family member 1Genealiases: ACAS2L · ACECS1 · AceCS2L
Q-omics provides the consensus-scored ACSS1 profile across patient tissues and cancer cell-line models. ACSS1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ACSS1 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, ACSS1 protein abundance shows 22,818 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, THCA, and GBM as cancer lineages where ACSS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACSS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACSS1 survival associations across molecular data types. ACSS1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACSS1 RNA expression–survival associations across cancer types. High ACSS1 expression shows unfavorable associations in OV and ACC, but favorable associations in HNSC, KIRP, SCLC and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for ACSS1 RNA expression.
This table summarizes ACSS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ACSS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACSS1 shows lower tumor expression in THCA, LUAD, KIRP and KIRC and higher tumor expression in HNSC and CHOL. The THCA box plot shows higher ACSS1 RNA expression in normal versus tumor tissue (log2 FC = −0.808, t-test p < 0.001).
This table shows molecular features associated with ACSS1 in patient tissues and cancer cell lines. In patient samples, ACSS1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ACSS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
